期刊
REPRODUCTIVE SCIENCES
卷 22, 期 4, 页码 476-483出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1933719114549850
关键词
clinical pharmacology; pharmacokinetic; ulipristal acetate; uterine fibroid
资金
- PregLem SA, a member of the Gedeon Richter Group
- Watson Laboratories, Inc. a subsidiary of Actavis, Inc.
- Actavis, Inc.
Uterine fibroids are benign hormone-sensitive tumors of uterine smooth muscle cells leading to heavy menstrual bleeding and pelvic pain. Ulipristal acetate (UPA) is an emerging medical treatment of fibroids with the potential to be used for long-term treatment. In this context, the present article summarizes UPA's main clinical pharmacology and pharmacokinetic (PK) properties. Ulipristal acetate has good oral bioavailability and a half-life allowing one single oral administration per day for the management of fibroids. As a steroid, UPA is a substrate for cytochrome P450 (CYP) 3A4 but does not act as an inducer or inhibitor of the CYP system or transporter proteins. With the exception of drugs modulating CYP3A4 activity, risks of drug-drug interactions with UPA are unlikely. In conclusion, besides its pharmacodynamic characteristics, UPA shows favorable PK properties that contribute to a good efficacy-safety ratio for the long-term management of uterine fibroids in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据